Synonyms
Plasminogen activator inhibitor; PAI; PAI-1; PLANH1; Plasminogen activator inhibitor 1; Serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1; Serpin E1; Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1; SERPINE1
BMAL-1: ARNTL; Aryl Hydrocarbon Receptor Nuclear Translocator Like
Plasminogen activator inhibitor-2; PAI-2: SERPINEB2; PLANH2; Plasminogen activator inhibitor-3; PAI-3: PCI; PLNH3; SERPINA5
tPA: tissue plasminogen acitvator, PLAT; Plasminogen Activator, Tissue Type
uPA: PLAU; Plasminogen Activator, urokinase-type plasminogen activator
Historical Background
The fibrinolysis complex includes a serine protease inhibitor (SERPIN), type-1 plasminogen activator inhibitor (PAI-1), and its target serine proteinases, the urokinase, and tissue-type plasminogen activators (uPA and tPA). As serine proteases, uPA and tPA coordinate various physiological functions, including...
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Agirbasli M. Pivotal role of plasminogen-activator inhibitor 1 in vascular disease. Int J Clin Pract. 2005;59(1):102–6. https://doi.org/10.1111/j.1742-1241.2005.00379.x.
Agirbasli D, Agirbasli M, Williams SM, Phillips 3rd JA. Interaction among 5,10 methylenetetrahydrofolate reductase, plasminogen activator inhibitor and endothelial nitric oxide synthase gene polymorphisms predicts the severity of coronary artery disease in Turkish patients. Coron Artery Dis. 2006;17(5):413–7.
Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes. 1997;46:860–7.
Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation. 1989;79:101–6.
Balsara RD, Ploplis VA. Plasminogen activator inhibitor-1: the double-edged sword in apoptosis. Thromb Haemost. 2008;100(6):1029–36. https://doi.org/10.1160/TH08-07-0427.
Berkenpas MB, Lawrence DA, Ginsburg D. Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J. 1995;14(13):2969–77.
Brogren H, Sihlbom C, Wallmark K, Lönn M, Deinum J, Karlsson L, et al. Heterogeneous glycosylation patterns of human PAI-1 may reveal its cellular origin. Thromb Res. 2008;122(2):271–81. https://doi.org/10.1016/j.thromres.2008.04.008.
Bulut EC, Abueid L, Ercan F, Süleymanoğlu S, Ağırbaşlı M, Yeğen BÇ. Treatment with oestrogen-receptor agonists or oxytocin in conjunction with exercise protects against myocardial infarction in ovariectomized rats. Exp Physiol. 2016;101(5):612–27. https://doi.org/10.1113/EP085708.
Busso N, Nicodeme E, Chesne C, Guillouzo A, Belin D, Hyafil F. Urokinase and type I plasminogen activator inhibitor production by normal human hepatocytes: modulation by inflammatory agents. Hepatology. 1994;20:186–90.
Chandler WL. A kinetic model of the circulatory regulation of tissue plasminogen activator. Thromb Haemost. 1991;66(3):321–8.
Ciarleglio CM, Ryckman KK, Servick SV, Hida A, Robbins S, Wells N, et al. Genetic differences in human circadian clock genes among worldwide populations. J Biol Rhythm. 2008;23(4):330–40. https://doi.org/10.1177/0748730408320284.
Coleman PL, Barouski PA, Gelehrter TD. The dexamethasone-induced inhibitor of fibrinolytic activity in hepatoma cells. A cellular product which specifically inhibits plasminogen activation. J Biol Chem. 1982;257:4260–4.
Davis GL. Fibrinolysis inhibitors. Clin Lab Sci. 1997;10(4):212–8.
Declerck PJ, De Mol M, Alessi MC, Baudner S, Paques EP, Preissner KT, et al. Purification and characterization of a plasminogen activator inhibitor-1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem. 1988;263(30):15454–61.
Draxler DF, Medcalf RL. The fibrinolytic system-more than fibrinolysis? Transfus Med Rev. 2015;29(2):102–9. https://doi.org/10.1016/j.tmrv.2014.09.006.
Durand MK, Bødker JS, Christensen A, Dupont DM, Hansen M, Jensen JK, et al. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb Haemost. 2004;91(3):438–49. https://doi.org/10.1160/TH03-12-0784.
Elokdah H, Abou-Gharbia M, Hennan JK, McFarlane G, Mugford CP, Krishnamurthy G, et al. Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization. J Med Chem. 2004;47(14):3491–4. https://doi.org/10.1021/jm049766q.
Eren M, Painter CA, Atkinson JB, Declerck PJ, Vaughan DE. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation. 2002;106:491–6.
Eren M, Painter CA, Gleaves LA, Schoenhard JA, Atkinson JB, Brown NJ, et al. Tissue- and agonist-specific regulation of human and murine plasminogen activator inhibitor-1 promoters in transgenic mice. J Thromb Haemost. 2003;1:2389–96.
Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest. 1984;74:1465–72.
Erickson LA, Schleef RR, Ny T, Loskutoff DJ. The fibrinolytic system of the vascular wall. Clin Haematol. 1985;14:513–30.
Eriksson P, Kallin B, van’t Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Nat Acad Sci. 1995;92:1851–5.
Flevaris P, Vaughan D. The role of plasminogen activator inhibitor type-1 in fibrosis. Semin Thromb Hemost. 2017 Mar;43(2):169–177.
Forsgren M, Raden B, Israelsson M, Larsson K, Heden LO. Molecular cloning and characterization of a full-length cDNA clone for human plasminogen. FEBS Lett. 1987;213(2):254–60.
Fortenberry YM. Plasminogen activator inhibitor-1 inhibitors: a patent review (2006-present). Expert Opin Ther Pat. 2013;23(7):801–15. https://doi.org/10.1517/13543776.2013.782393.
Ginsburg D, Zeheb R, Yang AY, Rafferty UM, Andreasen PA, Nielsen L, et al. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest. 1986;78:1673–80. https://doi.org/10.1172/JCI112761.
Gorlatova NV, Cale JM, Elokdah H, Li D, Fan K, Warnock M, et al. Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor. J Biol Chem. 2007;282(12):9288–96. https://doi.org/10.1074/jbc.M611642200.
Hedstrom L. Serine protease mechanism and specificity. Chem Rev. 2002;102(12):4501–24. https://doi.org/10.1021/cr000033x.
Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem. 1985;260:11581–7.
Hennan JK, Morgan GA, Swillo RE, Antrilli TM, Mugford C, Vlasuk GP, et al. Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis. J Thromb Haemost. 2008;6(9):1558–64. https://doi.org/10.1111/j.1538-7836.2008.03063.x.
Huang J, Sabater-Lleal M, Asselbergs FW, Tregouet D, Shin SY, Ding J, et al. Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation. Blood. 2012;120(24):4873–81. https://doi.org/10.1182/blood-2012-06-436188.
Kaji H. Adipose tissue-derived plasminogen activator inhibitor-1 function and regulation. Compr Physiol. 2016;6(4):1873–96. https://doi.org/10.1002/cphy.c160004.
Klinger KW, Winqvist R, Riccio A, Andreasen PA, Sartorio R, Nilesen LS, et al. Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sci U S A. 1987;84(23):8548–52.
Kortlever RM, Higgins PJ, Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol. 2006;8(8):877–84. https://doi.org/10.1038/ncb1448.
Kruithof EK. Plasminogen activator inhibitors – a review. Enzyme. 1988;40:113–21.
Kruithof EK, Trab-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood. 1984;64:907–13.
Kruithof EK, Vasalli JD, Schleuning WD, Mattaliano RJ, Bachmann F. Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J Biol Chem. 1986;261:11207–13.
Kurnik PB. Circadian variation in the efficacy of tissue-type plasminogen activator. Circulation. 1995;91:1341–6.
Lademann U, Rømer MU, Jensen PB, Hofland KF, Larsen L, Christensen IJ, Brünner N. Malignant transformation of wild-type but not plasminogen activator inhibitor-1 gene-deficient fibroblasts decreases cellular sensitivity to chemotherapy-mediated apoptosis. Eur J Cancer. 2005;41(7):1095–100.
Lawrence DA, Olson ST, Palaniappan S, Ginsburg D. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability. Biochemistry. 1994;33(12):3643–8.
Lindahl TL, Sigurdardottir O, Wiman B. Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost. 1989;62(2):748–51.
Loskutoff DJ, van Mourik JA, Erickson LA, Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA. 1983;80:2956–60.
Lundgren CH, Brown SL, Nordt TK, Sobel BE, Fujii S. Elaboration of type-1 plasminogen activator inhibitor from adipocytes. Circulation. 1996;93:106–10.
Maemura K, de la Monte SM, Chin MT, Layne MD, Hsieh CM, Yet SF, et al. CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 gene expression. J Biol Chem. 2000 Nov 24;275(47):36847–51. https://doi.org/10.1074/jbc.C000629200.
Maemura K, Takeda N, Nagai R. Circadian rhythms in the CNS and peripheral clock disorders: role of the biological clock in cardiovascular diseases. J Pharmacol Sci. 2007;103(2):134–8. https://doi.org/10.1254/jphs.FMJ06003X2.
Meijers JC, Herwald H. Protein C inhibitor. Semin Thromb Hemost. 2011;37(4):349–54. https://doi.org/10.1055/s-0031-1276583.
Nordenhem A, Wiman B. Plasminogen activator inhibitor-1 (PAI-1) content in platelets from healthy individuals genotyped for the 4G/5G polymorphism in the PAI-1 gene. Scand J Clin Lab Invest. 1997;57:453–61.
Oishi K. Plasminogen activator inhibitor-1 and the circadian clock in metabolic disorders. Clin Exp Hypertens. 2009;31(3):208–19. https://doi.org/10.1080/10641960902822468.
Pei X, Zhang J, Liu J. Clinical applications of nucleic acid aptamers in cancer. Mol Clin Oncol. 2014;2:341–8. https://doi.org/10.3892/mco.2014.255.
Placencio VR, DeClerck YA. Plasminogen activator inhibitor-1 in cancer: rationale and insight for future therapeutic testing. Cancer Res. 2015;75(15):2969–74. https://doi.org/10.1158/0008-5472.CAN-15-0876.
Rouch A, Vanucci-Bacque C, Bedos-Belval F, Baltas M. Small molecules inhibitors of plasminogen activator inhibitor-1—an overview. Eur J Med Chem. 2015;92:619–36. https://doi.org/10.1016/j.ejmech.2015.01.010.
Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest. 1991;88:1346–53. https://doi.org/10.1172/JCI115440.
Schleef RR, Loskutoff DJ. Fibrinolytic system of vascular endothelial cells. Role of plasminogen activator inhibitors. Haemostasis. 1988;18:328–41.
Schneider DJ, Chen Y, Sobel BE. The effect of plasminogen activator inhibitor type 1 on apoptosis. Thrombosis and haemostasis. 2008;100(6):1037–40 doi: 10.1160/TH08-04-0234.
Sobel B, Woodcock-Mitchell J, Schneider D, Holt R, Marutsuka K, Gold H. Increased plasminogen activator inhibitor type-1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation. 1998;97:2213–21. https://doi.org/10.1161/01.CIR.97.22.2213.
Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha beta3 binding to vitronectin. Nature. 1996;383:441–3. https://doi.org/10.1038/383441a0.
Taymaz H, Erarslan S, Oner ET, Alkan T, Ağirbaşli M, Kirdar B. Sequence variations within the genes related to hemostatic imbalance and their impact on coronary artery disease in Turkish population. Thromb Res. 2007;119(1):55–62. https://doi.org/10.1016/j.thromres.2005.12.018.
Vaughan DE. PAI-1: a common denominator in cardiovascular disease. J Investig Med. 1998;46:370–6.
Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost. 2005;3:1879–83. https://doi.org/10.1111/j.1538-7836.2005.01420.x.
Wang ZH, Ren WY, Zhu L, Hu LJ. Plasminogen activator inhibitor-1 regulates LPS induced inflammation in rat macrophages through autophagy activation. Sci World J. 2014;2014:189168. https://doi.org/10.1155/2014/189168.
White MJ, Kodaman NM, Harder RH, Asselbergs FW, Vaughan DE, Brown NJ, et al. Genetics of plasminogen activator inhibitor-1 (PAI-1) in a Ghanaian population. PLoS One. 2015;10(8):e0136379. https://doi.org/10.1371/journal.pone.0136379.
Yasar Yildiz S, Kuru P, Toksoy Oner E, Agirbasli M. Functional stability of plasminogen activator inhibitor-1. Sci World J. 2014;2014:858293. https://doi.org/10.1155/2014/858293.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this entry
Cite this entry
Agirbasli, D., Agirbasli, M. (2018). Plasminogen Activator Inhibitor-1. In: Choi, S. (eds) Encyclopedia of Signaling Molecules. Springer, Cham. https://doi.org/10.1007/978-3-319-67199-4_101797
Download citation
DOI: https://doi.org/10.1007/978-3-319-67199-4_101797
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-67198-7
Online ISBN: 978-3-319-67199-4
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences